In the wound-healing assay, treatment with inhibitors of BUB1, CHEK1, or PLK1 significantly delayed wound closure in both MDA-MB-231 and BT-549 triple-negative BC cell lines, indicating impaired migratory capacity (Figure 3A,B, Table S6). Here, BUB1 is linked to breast cancer.